As the first quarter of 2025 comes to a close, Mereo BioPharma (MREO, Financial) is poised for a milestone-rich year. The company’s Phase 3 Orbit study of setrusumab, targeting osteogenesis imperfecta, is expected to yield results by mid-2025 during the second interim analysis or in the fourth quarter at the final review.
Preparations are underway for setrusumab's launch in Europe, contingent upon regulatory approvals. Additionally, alvelestat has reached Phase 3 readiness, with trial start-up activities being finalized to advance ongoing partnership efforts. Mereo BioPharma is strategically managing its funds to maintain operations up to 2027, emphasizing the importance of its late-stage pipeline developments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Mereo BioPharma Group PLC (MREO, Financial) is $7.47 with a high estimate of $9.92 and a low estimate of $5.65. The average target implies an upside of 198.63% from the current price of $2.50. More detailed estimate data can be found on the Mereo BioPharma Group PLC (MREO) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Mereo BioPharma Group PLC's (MREO, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
